Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 878

1.

AUTHOR REPLY.

Kaplan SA.

Urology. 2019 Dec;134:202. doi: 10.1016/j.urology.2019.07.045. No abstract available.

PMID:
31789182
2.

Re: Incidence of Type 2 Diabetes Mellitus in Men Receiving Steroid 5α-Reductase Inhibitors: Population Based Cohort Study.

Kaplan SA.

J Urol. 2019 Oct;202(4):634. doi: 10.1097/JU.0000000000000447. Epub 2019 Sep 6. No abstract available.

PMID:
31766086
3.

Re: Management of Male Lower Urinary Tract Symptoms in a Simulated, Over-the-Counter Setting: An Exploratory Study of Tamsulosin.

Kaplan SA.

J Urol. 2019 Oct;202(4):636. doi: 10.1097/01.JU.0000577556.96605.da. Epub 2019 Sep 6. No abstract available.

PMID:
31766085
5.

Re: Serum Cholesterol and Risk of Lower Urinary Tract Symptoms Progression: Results from the Reduction by Dutasteride of Prostate Cancer Events Study.

Kaplan SA.

J Urol. 2019 Oct;202(4):635. doi: 10.1097/01.JU.0000577548.11853.63. Epub 2019 Sep 6. No abstract available.

PMID:
31766083
6.

Re: Alpha-Blockers with or without Phosphodiesterase Type 5 Inhibitor for Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.

Kaplan SA.

J Urol. 2019 Nov 11:10109701JU0000614748557029c. doi: 10.1097/01.JU.0000614748.55702.9c. [Epub ahead of print] No abstract available.

PMID:
31710569
7.

Re: Real-World Evidence of Prostatic Urethral Lift Confirms Pivotal Clinical Study Results: 2-Year Outcomes of a Retrospective Multicenter Study.

Kaplan SA.

J Urol. 2019 Nov 11:101097JU0000000000000645. doi: 10.1097/JU.0000000000000645. [Epub ahead of print] No abstract available.

PMID:
31710565
8.

Re: Laser Prostate Ablation and Enucleation: Analysis of a National Cohort.

Kaplan SA.

J Urol. 2019 Nov 11:10109701JU00006147441758456. doi: 10.1097/01.JU.0000614744.17584.56. [Epub ahead of print] No abstract available.

PMID:
31710552
9.

Re: Do Patients Have to Choose between Ejaculation and Miction? A Systematic Review about Ejaculation Preservation Technics for Benign Prostatic Obstruction Surgical Treatment.

Kaplan SA.

J Urol. 2019 Nov 11:10109701JU000061474009960c4. doi: 10.1097/01.JU.0000614740.09960.c4. [Epub ahead of print] No abstract available.

PMID:
31710545
10.

How Practice Facilitation Strategies Differ by Practice Context.

Nguyen AM, Cuthel A, Padgett DK, Niles P, Rogers E, Pham-Singer H, Ferran D, Kaplan SA, Berry C, Shelley D.

J Gen Intern Med. 2019 Oct 21. doi: 10.1007/s11606-019-05350-7. [Epub ahead of print]

PMID:
31637651
11.

Re: Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study.

Kaplan SA.

J Urol. 2019 Oct 18:101097JU0000000000000604. doi: 10.1097/JU.0000000000000604. [Epub ahead of print] No abstract available.

PMID:
31625800
12.

Re: In-Hospital Cost Analysis of Prostatic Artery Embolization Compared with Transurethral Resection of the Prostate: Post Hoc Analysis of a Randomized Controlled Trial.

Kaplan SA.

J Urol. 2019 Oct 18:10109701JU00006049681956305. doi: 10.1097/01.JU.0000604968.19563.05. [Epub ahead of print] No abstract available.

PMID:
31625795
13.

Re: The Association between Local Atherosclerosis of the Prostatic Artery and Benign Prostatic Enlargement in Humans: Putative Mechanism of Chronic Ischemia for Prostatic Enlargement.

Kaplan SA.

J Urol. 2019 Oct 18:10109701JU00006049760431625. doi: 10.1097/01.JU.0000604976.04316.25. [Epub ahead of print] No abstract available.

PMID:
31625791
14.

Development of a Measure of Informal Workplace Social Interactions.

Winslow CJ, Sabat IE, Anderson AJ, Kaplan SA, Miller SJ.

Front Psychol. 2019 Sep 20;10:2043. doi: 10.3389/fpsyg.2019.02043. eCollection 2019.

15.

Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial.

Sebastianelli A, Spatafora P, Frizzi J, Saleh O, De Nunzio C, Tubaro A, Vignozzi L, Maggi M, Serni S, McVary KT, Kaplan SA, Gravas S, Chapple C, Gacci M.

Eur Urol Focus. 2019 Oct 9. pii: S2405-4569(19)30291-3. doi: 10.1016/j.euf.2019.09.015. [Epub ahead of print]

PMID:
31606473
16.

Ejaculatory Preserving Middle Lobe Onl-Transurethral Resection and Vaporization of the Prostate: 12-Year Experience.

Gul Z, Chughtai B, Te AE, Thomas D, Kaplan SA.

Urology. 2019 Dec;134:199-202. doi: 10.1016/j.urology.2019.07.042. Epub 2019 Sep 26.

PMID:
31563537
17.

Re: Aquablation versus Transurethral Resection of the Prostate: 1 Year United States-Cohort Outcomes.

Kaplan SA.

J Urol. 2019 Dec;202(6):1072-1074. doi: 10.1097/JU.0000000000000544. Epub 2019 Sep 12. No abstract available.

PMID:
31512973
18.

Re: Systemic Comorbidity Burden Using the ACTIONS Phenotype Predicts Urologic Medication Discontinuation following Transurethral Resection of the Prostate.

Kaplan SA.

J Urol. 2019 Dec;202(6):1073. doi: 10.1097/01.JU.0000585160.88401.5d. Epub 2019 Sep 12. No abstract available.

PMID:
31512966
19.

Re: Urodynamic Outcomes after Aquablation.

Kaplan SA.

J Urol. 2019 Dec;202(6):1073-1074. doi: 10.1097/01.JU.0000585164.26520.69. Epub 2019 Sep 12. No abstract available.

PMID:
31512963
20.

Clinician Perspectives on the Benefits of Practice Facilitation for Small Primary Care Practices.

Rogers ES, Cuthel AM, Berry CA, Kaplan SA, Shelley DR.

Ann Fam Med. 2019 Aug 12;17(Suppl 1):S17-S23. doi: 10.1370/afm.2427.

21.

Re: Prostate Artery Embolization in Patients with Prostate Volumes of 80 mL or More: A Single-Institution Retrospective Experience of 93 Patients.

Kaplan SA.

J Urol. 2019 Nov;202(5):841-842. doi: 10.1097/JU.0000000000000489. Epub 2019 Oct 9. No abstract available.

PMID:
31403924
22.

Re: Association of Treatment with 5α-Reductase Inhibitors with Time to Diagnosis and Mortality in Prostate Cancer.

Kaplan SA.

J Urol. 2019 Nov;202(5):842-843. doi: 10.1097/01.JU.0000579864.64850.82. Epub 2019 Oct 9. No abstract available.

PMID:
31403923
23.

Re: Oxidative Damage in Patients with Benign Prostatic Hyperplasia and Prostate Cancer Co-Exposed to Phthalates and to Trace Elements.

Kaplan SA.

J Urol. 2019 Nov;202(5):842. doi: 10.1097/01.JU.0000579860.87720.a7. Epub 2019 Oct 9. No abstract available.

PMID:
31403918
24.

Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial.

Sebastianelli A, Spatafora P, Frizzi J, Saleh O, Sessa M, De Nunzio C, Tubaro A, Vignozzi L, Maggi M, Serni S, McVary KT, Kaplan SA, Gravas S, Chapple C, Gacci M.

J Clin Med. 2019 Jul 29;8(8). pii: E1126. doi: 10.3390/jcm8081126.

25.
26.

Re: Development of a Clinically Relevant Men's Health Phenotype and Correlation of Systemic and Urologic Conditions.

Kaplan SA.

J Urol. 2019 Sep;202(3):435-436. doi: 10.1097/01.JU.0000574468.70527.90. Epub 2019 Aug 8. No abstract available.

PMID:
31219384
27.

Re: Histotripsy Treatment of Benign Prostatic Enlargement Using the Vortx Rx System: Initial Human Safety and Efficacy Outcomes.

Kaplan SA.

J Urol. 2019 Sep;202(3):434. doi: 10.1097/JU.0000000000000410. Epub 2019 Aug 8. No abstract available.

PMID:
31219380
28.

Re: Extreme Price Variation for Generic Benign Prostatic Hyperplasia Medications.

Kaplan SA.

J Urol. 2019 Sep;202(3):436-437. doi: 10.1097/01.JU.0000574472.78150.e0. Epub 2019 Aug 8. No abstract available.

PMID:
31219374
29.

BPH: Why Do Patients Fail Medical Therapy?

Gul ZG, Kaplan SA.

Curr Urol Rep. 2019 Jun 6;20(7):40. doi: 10.1007/s11934-019-0899-z. Review.

PMID:
31168725
30.

Re: Recovery of Voiding Efficiency and Bladder Function in Male Patients with Non-Neurogenic Detrusor Underactivity after Transurethral Bladder Outlet Surgery.

Kaplan SA.

J Urol. 2019 Jun;201(6):1031. doi: 10.1097/01.JU.0000559577.83383.91. No abstract available.

PMID:
31067615
31.

Editorial Comment.

Kaplan SA.

J Urol. 2019 Aug;202(2):368. doi: 10.1097/01.JU.0000558699.49982.45. Epub 2019 Jul 8. No abstract available.

PMID:
31042134
32.

Re: Allopurinol and Risk of Benign Prostatic Hyperplasia in a Finnish Population-Based Cohort.

Kaplan SA.

J Urol. 2019 Aug;202(2):184. doi: 10.1097/JU.0000000000000306. Epub 2019 Jul 8. No abstract available.

PMID:
31021294
33.

Re: Convective Radiofrequency Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia: A Single Office Experience.

Kaplan SA.

J Urol. 2019 Aug;202(2):184-185. doi: 10.1097/01.JU.0000558254.04859.e2. Epub 2019 Jul 8. No abstract available.

PMID:
31021289
34.

Re: Association of Prostatic Volume and Carotid Intima-Media Thickness in Patients with Benign Prostatic Hyperplasia.

Kaplan SA.

J Urol. 2019 Aug;202(2):185-186. doi: 10.1097/01.JU.0000558255.12483.b5. Epub 2019 Jul 8. No abstract available.

PMID:
31021287
35.

Re: Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.

Kaplan SA.

J Urol. 2019 May;201(5):832. doi: 10.1097/JU.0000000000000180. No abstract available.

PMID:
31009978
36.

Re: Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) with Haematuria in the Absence of an Upper Urinary Tract Pathology.

Kaplan SA.

J Urol. 2019 May;201(5):834-835. doi: 10.1097/01.JU.0000554113.47614.7d. No abstract available.

PMID:
31009977
37.

Re: Hyperthyroidism is Not a Significant Risk of Benign Prostatic Hyperplasia: A Nationwide Population-Based Study.

Kaplan SA.

J Urol. 2019 May;201(5):833. doi: 10.1097/01.JU.0000554111.39991.66. No abstract available.

PMID:
31009970
39.

Re: rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: 4-Year Results from Randomized Controlled Study.

Kaplan SA.

J Urol. 2019 Jul;202(1):5. doi: 10.1097/JU.0000000000000260. Epub 2019 Jun 7. No abstract available.

PMID:
30973301
40.

Re: Polypharmacy, Chronic Kidney Disease, and Benign Prostatic Hyperplasia in Patients with Chronic Obstructive Pulmonary Disease Newly Treated with Long-Acting Anticholinergics.

Kaplan SA.

J Urol. 2019 Jul;202(1):6-7. doi: 10.1097/01.JU.0000557737.50592.3d. Epub 2019 Jun 7. No abstract available.

PMID:
30958737
41.

Re: Variants of Patterns of Intra- and Extra-Prostatic Arterial Distribution of the Prostatic Artery Applied to Prostatic Artery Embolization: Proposal of a Classification.

Kaplan SA.

J Urol. 2019 Jul;202(1):6. doi: 10.1097/01.JU.0000557736.42968.f9. Epub 2019 Jun 7. No abstract available.

PMID:
30958734
42.

Re: Ethanol Extract of Evodia rutaecarpa Attenuates Cell Growth through Caspase-Dependent Apoptosis in Benign Prostatic Hyperplasia-1 Cells.

Kaplan SA.

J Urol. 2019 Jun;201(6):1030. doi: 10.1097/01.JU.0000554644.86435.6c. No abstract available.

PMID:
30864929
43.
44.

Re: Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia: A Feasibility Study.

Kaplan SA.

J Urol. 2018 Dec;200(6):1139-1140. doi: 10.1016/j.juro.2018.09.014. No abstract available.

PMID:
30838905
46.

Re: Learning Curves and Perioperative Outcomes after Endoscopic Enucleation of the Prostate: A Comparison between GreenLight 532-nm and Holmium Lasers.

Kaplan SA.

J Urol. 2018 Dec;200(6):1139. doi: 10.1016/j.juro.2018.09.013. No abstract available.

PMID:
30835613
47.

Re: Association between Chronic Obstructive Pulmonary Disease and Increased Risk of Benign Prostatic Hyperplasia: A Retrospective Nationwide Cohort Study.

Kaplan SA.

J Urol. 2018 Dec;200(6):1138-1141. doi: 10.1016/j.juro.2018.09.012. No abstract available.

PMID:
30822192
48.
49.

Re: Long-Term Dutasteride Therapy in Men with Benign Prostatic Hyperplasia Alters Glucose and Lipid Profiles and Increases Severity of Erectile Dysfunction.

Kaplan SA.

J Urol. 2019 Mar;201(3):416-417. doi: 10.1097/01.JU.0000553653.09278.18. No abstract available.

PMID:
30759626
50.

Re: Comparison of Perioperative Outcomes between Holmium Laser Enucleation of the Prostate and Robot-Assisted Simple Prostatectomy.

Kaplan SA.

J Urol. 2019 Mar;201(3):416. doi: 10.1097/01.JU.0000553652.82773.7e. No abstract available.

PMID:
30759625

Supplemental Content

Loading ...
Support Center